Literature DB >> 27441745

Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Eric D Brooks1, Jonathan E Schoenhals, Chad Tang, Goran Micevic, Daniel R Gomez, Joe Y Chang, James W Welsh.   

Abstract

Immunotherapy, particularly immune-checkpoint inhibition, is producing encouraging clinical responses and affecting the way numerous cancers are treated. Yet immune-checkpoint therapy is not effective for many patients, and even those who initially respond can experience relapse, fueling interest in finding new processes or tools to improve the effectiveness of these novel therapeutics. One such tool is radiation. Both preclinical and clinical studies have demonstrated that the systemic effects of immunotherapy can be amplified when it is used in combination with radiation and, conversely, that the immunogenic effects of local irradiation can be amplified and extended to distant sites when used with immunotherapy. We review how stereotactic ablative radiation therapy, a technique specifically indicated for tumors treated with immune-checkpoint inhibitors, can potentiate the effects of immune-checkpoint therapy. We further explore how these novel therapeutics may transform radiation, previously considered a local treatment option, into powerful systemic therapy.

Entities:  

Mesh:

Year:  2016        PMID: 27441745      PMCID: PMC5812885          DOI: 10.1097/PPO.0000000000000210

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  130 in total

Review 1.  Oncolytic viruses and their application to cancer immunotherapy.

Authors:  E Antonio Chiocca; Samuel D Rabkin
Journal:  Cancer Immunol Res       Date:  2014-04       Impact factor: 11.151

2.  Immune effects of targeted radiation therapy for cancer.

Authors:  Vishwajith Sridharan; Jonathan D Schoenfeld
Journal:  Discov Med       Date:  2015-03       Impact factor: 2.970

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.

Authors:  P R Rogers; J Song; I Gramaglia; N Killeen; M Croft
Journal:  Immunity       Date:  2001-09       Impact factor: 31.745

5.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

6.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Authors:  S F Slovin; C S Higano; O Hamid; S Tejwani; A Harzstark; J J Alumkal; H I Scher; K Chin; P Gagnier; M B McHenry; T M Beer
Journal:  Ann Oncol       Date:  2013-03-27       Impact factor: 32.976

7.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

8.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Authors:  Inge Verbrugge; Jim Hagekyriakou; Leslie L Sharp; Mara Galli; Alison West; Nicole M McLaughlin; Hélène Duret; Hideo Yagita; Ricky W Johnstone; Mark J Smyth; Nicole M Haynes
Journal:  Cancer Res       Date:  2012-05-08       Impact factor: 12.701

9.  Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma--a case report.

Authors:  Mamiko Takaya; Yuzuru Niibe; Shinpei Tsunoda; Toshiko Jobo; Manami Imai; Syoko Kotani; Nobuya Unno; Kazushige Hayakawa
Journal:  Anticancer Res       Date:  2007 Jan-Feb       Impact factor: 2.480

10.  Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective.

Authors:  Julian Burks; Ryan E Reed; Shyamal D Desai
Journal:  Oncotarget       Date:  2015-03-30
View more
  14 in total

Review 1.  Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.

Authors:  Jonathan E Schoenhals; Steven N Seyedin; Clark Anderson; Eric D Brooks; Yun R Li; Ahmed I Younes; Sharareh Niknam; Ailin Li; Hampartsoum B Barsoumian; Maria Angelica Cortez; James W Welsh
Journal:  Transl Lung Cancer Res       Date:  2017-04

2.  Stereotactic body radiotherapy versus conventional radiotherapy for early-stage small cell lung cancer.

Authors:  Neil B Newman; Alexander D Sherry; Daniel W Byrne; Evan C Osmundson
Journal:  J Radiat Oncol       Date:  2019-07-04

3.  Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines.

Authors:  Yangle Huang; Yuanli Dong; Jingfang Zhao; Lijia Zhang; Lin Kong; Jiade Jay Lu
Journal:  Ann Transl Med       Date:  2019-10

4.  The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients.

Authors:  Shang-Jui Wang; Sachin R Jhawar; Zorimar Rivera-Nunez; Ann W Silk; John Byun; Eric Miller; Dukagjin Blakaj; Rahul R Parikh; Joseph Weiner; Sharad Goyal
Journal:  Cureus       Date:  2020-06-22

5.  Stereotactic Body Radiotherapy as an Alternative to Definitive Surgery in Cancers of Various Organs.

Authors:  Yuta Shibamoto; Hiroshi Onishi
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 6.  [Research Progress of Immunotherapy for Brain Metastases in Patients 
with Drive Gene Negative NSCLC].

Authors:  Shuang Zhang; Jingjing Liu; Changliang Yang; Shuang Li; Ying Cheng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-08-20

7.  Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade.

Authors:  W Tristram Arscott; Simeng Zhu; John P Plastaras; Amit Maity; Michelle Alonso-Basanta; Joshua Jones
Journal:  Neurooncol Pract       Date:  2018-10-25

Review 8.  Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies.

Authors:  Jacob Ukleja; Erika Kusaka; David T Miyamoto
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

9.  A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.

Authors:  Rohann J M Correa; Belal Ahmad; Andrew Warner; Craig Johnson; Mary J MacKenzie; Stephen E Pautler; Glenn S Bauman; George B Rodrigues; Alexander V Louie
Journal:  Radiat Oncol       Date:  2018-03-20       Impact factor: 3.481

Review 10.  Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.

Authors:  Shiqiang Wang; Chongling Hu; Fei Xie; Yanhui Liu
Journal:  Onco Targets Ther       Date:  2020-01-23       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.